Santen Pharmaceutical Co., Ltd. American Depositary Receipt (SNPHY)
OTC
10.69
+0.46 (+4.50%)
Closed
Oct 7, 2026
Day's Range
10.5910.69
52 wk Range
9.2213.93
Financial Statements - SNPHY - Santen Pharmaceutical Co., Ltd. American Depositary Receipt
Revenue
291.62B▼ 2.8%
Net Income
37.56B▲ 4.8%Net Margin 12.9%
EBITDA
58.20B▼ 1.4%
Free Cash Flow
419.66M▼ 96.7%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Sales | 291.62B | 300B | 2.04B | 279.03B | 266.25B | 249.60B |
| Cost of Goods | 121.88B | 128.97B | 834.81M | 112.95B | 109.67B | 98.22B |
| Gross Profit | 169.74B | 171.02B | 1.21B | 166.08B | 156.58B | 151.38B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 47.79B | 46.88B | 261.03M | -3.09B | 35.88B | 12.18B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 47.44B | 47.48B | 202.33M | -5.79B | 35.61B | 11.68B |
| Income Tax | 9.88B | 11.62B | 21.47M | 9.18B | 8.42B | 2.56B |
| Net Income | 37.56B | 35.85B | 180.85M | -14.98B | 27.18B | 9.12B |
| EPS Basic | 114.04 | 103.98 | 72.59 | -38.6 | 68.07 | 23.3 |
| EPS Diluted | 113.8 | 103.68 | 72.37 | -38.6 | 67.97 | 23.26 |
| Basic Shares Outstanding | 327.68M | 348.68M | 2.48M | 387.42M | 61.83B | 61.78B |
| Diluted Shares Outstanding | 327.68M | 348.68M | 2.48M | 387.42M | 61.83B | 61.78B |
| Ebit | 49.43B | 50.19B | 220.37M | -4.30B | 36.82B | 13.17B |
| Ebitda | 58.20B | 59B | 343.49M | 12.94B | 53.88B | 30.67B |
| Net Income Continuous Operations | - | - | 180.85M | -14.98B | 27.18B | 9.12B |
| Minority Interests | -192M | 403M | -60M | 35M | 29M | 185M |
| Preferred Stock Dividends | 8M | 9M | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
